东方生物
(688298)
| 流通市值：55.96亿 | | | 总市值：55.96亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 4,879,469,153.29 | 5,496,264,243.18 | 6,296,336,057.74 | 6,596,974,597.32 |
| 应收票据及应收账款 | 246,839,672.98 | 275,229,157.19 | 377,145,175.45 | 309,357,083.07 |
| 应收账款 | 246,839,672.98 | 275,229,157.19 | 377,145,175.45 | 309,357,083.07 |
| 预付款项 | 49,069,594.63 | 46,229,023.05 | 81,373,296.43 | 62,903,926.52 |
| 其他应收款合计 | 81,234,824.17 | 90,598,582.36 | 102,037,332.97 | 73,132,776.4 |
| 存货 | 429,538,632.32 | 414,320,414.6 | 372,535,494.43 | 431,919,112.51 |
| 其他流动资产 | 160,449,034.62 | 147,081,045.53 | 108,066,597.74 | 112,517,328.29 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 6,702,004,059.7 | 7,323,188,068.49 | 8,283,861,497.83 | 8,747,481,069.59 |
| 非流动资产: | | | | |
| 长期股权投资 | 19,725,328.51 | 20,580,043.78 | 20,851,156.83 | 21,039,271.48 |
| 其他非流动金融资产 | 28,866,871.97 | 29,314,988.87 | 28,743,768.22 | 14,549,124.82 |
| 固定资产 | 898,673,916.67 | 908,098,979.21 | 888,517,986.54 | 671,745,818.08 |
| 在建工程 | 651,851,731 | 533,217,684.2 | 427,123,183.76 | 369,990,260.92 |
| 使用权资产 | 24,375,104.15 | 31,868,617.12 | 32,589,464.86 | 32,505,022.31 |
| 无形资产 | 510,557,855.24 | 526,070,439.08 | 526,516,508.5 | 481,238,829.15 |
| 长期待摊费用 | 43,667,757.46 | 46,916,961.07 | 46,085,148.68 | 36,324,079.07 |
| 递延所得税资产 | 177,997,886.23 | 183,990,366.68 | 187,045,932.21 | 193,234,125.54 |
| 其他非流动资产 | 112,265,214.56 | 108,210,274.3 | 100,386,457.24 | 135,631,825.03 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,467,981,665.79 | 2,388,268,354.31 | 2,257,859,606.84 | 1,956,258,356.4 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 9,169,985,725.49 | 9,711,456,422.8 | 10,541,721,104.67 | 10,703,739,425.99 |
| 流动负债: | | | | |
| 短期借款 | 201,000,000 | 200,000,000 | 200,000,000 | - |
| 应付票据及应付账款 | 478,604,228.01 | 871,784,564.34 | 1,232,028,865.19 | 1,580,068,705.92 |
| 其中：应付票据 | 120,551,449.09 | 446,020,914.67 | 615,505,810.53 | 518,094,593.67 |
| 应付账款 | 358,052,778.92 | 425,763,649.67 | 616,523,054.66 | 1,061,974,112.25 |
| 合同负债 | 30,633,353.53 | 34,934,824.66 | 116,297,695.63 | 339,139,118.25 |
| 应付职工薪酬 | 32,022,038.19 | 30,230,542.49 | 32,573,617.7 | 156,913,180.02 |
| 应交税费 | 4,445,127.41 | 9,654,964.55 | 59,543,893.05 | 86,477,661.1 |
| 其他应付款合计 | 94,582,199.89 | 103,193,590.9 | 185,776,474.68 | 74,227,398.06 |
| 一年内到期的非流动负债 | 4,671,568.15 | 5,626,415.34 | 3,703,651.45 | 3,551,080.89 |
| 其他流动负债 | 1,888,335.52 | 1,689,329.32 | 352,053.2 | 38,103,486.8 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 847,846,850.7 | 1,257,114,231.6 | 1,830,276,250.9 | 2,278,480,631.04 |
| 非流动负债: | | | | |
| 长期借款 | 350,000,000 | 350,000,000 | 393,500,000 | 50,000,000 |
| 租赁负债 | 23,954,969.33 | 25,286,750.93 | 27,936,555.21 | 28,645,330.36 |
| 长期应付款 | 4,000,000 | 4,660,000 | 4,660,000 | 3,296,000 |
| 预计负债 | - | - | 3,390,000 | 3,390,000 |
| 递延收益 | 14,383,489.83 | 14,545,118.07 | 14,048,324.89 | 14,168,374.55 |
| 递延所得税负债 | 2,753,443.36 | 2,753,443.36 | 2,753,443.35 | 2,764,810.47 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 395,091,902.52 | 397,245,312.36 | 446,288,323.45 | 102,264,515.38 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,242,938,753.22 | 1,654,359,543.96 | 2,276,564,574.35 | 2,380,745,146.42 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 201,600,000 | 201,600,000 | 168,000,000 | 168,000,000 |
| 资本公积 | 403,177,585.86 | 403,177,585.86 | 436,107,197.19 | 436,321,288.19 |
| 其他综合收益 | 53,145,262.45 | 57,186,910.47 | 15,006,454.54 | 28,267,235.79 |
| 盈余公积 | 84,000,000 | 84,000,000 | 84,000,000 | 84,000,000 |
| 未分配利润 | 7,037,873,194.73 | 7,145,064,761.95 | 7,395,927,100.31 | 7,446,257,175.46 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 7,779,796,043.04 | 7,891,029,258.28 | 8,099,040,752.04 | 8,162,845,699.44 |
| 少数股东权益 | 147,250,929.23 | 166,067,620.56 | 166,115,778.28 | 160,148,580.13 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 7,927,046,972.27 | 8,057,096,878.84 | 8,265,156,530.32 | 8,322,994,279.57 |
| 负债和股东权益合计 | 9,169,985,725.49 | 9,711,456,422.8 | 10,541,721,104.67 | 10,703,739,425.99 |
| 公告日期 | 2023-10-31 | 2023-08-30 | 2023-04-28 | 2023-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |